Eisai files for full FDA approval for Alzheimer's drug Leqembi

US approval for new Alzheimer's drug

The US drug agency FDA has granted expedited approval for an antibody drug that is intended to slow the progression of Alzheimer's. However, there can also be serious side effects, as test series have shown. more Read the report at www.tagesschau.de

US approves new drug to treat Alzheimer's disease

WASHINGTON: The US Food and Drug Administration on Friday approved a highly anticipated new drug designed to slow cognitive decline in patients in mild and early stages of Alzheimer's disease.The...

US approves new drug to treat Alzheimer's disease

THE US Food and Drug Administration on Friday approved a highly anticipated new drug designed to slow cognitive decline in patients in mild and early stages of Alzheimer's disease.The FDA approval of the drug, Leqembi, also known as lecanemab, comes just days after the regulatory agency was harshly criticized in a congressional report for its green-lighting of another Alzheimer's drug, Aduhelm.And it was granted despite trial results showing the…

Eisai, Biogen get U.S. FDA approval for Alzheimer's drug, apply for full approval

The U.S. Food and Drug Administration on Friday approved the Alzheimer's drug lecanemab developed by Eisai Co Ltd and Biogen Inc for patients in the earliest stages of the mind-wasting disease.

US approves new drug to treat Alzheimer's disease

The new drug promises to slow down the progression of the disease and its impacts on the brain.

Eisai files for full FDA approval for Alzheimer's drug Leqembi

(Reuters) - Japanese drugmaker Eisai Co Ltd said on Saturday it had submitted an application to the U.S. Food and Drug Administration for a standard review of its Alzheimer's drug Leqembi, which was recently approved